Bioflares Ltd

We hope to catalyse the development of synthetic biomedicine: up to 6 parameter logic revealed in vitro (no cell lysis) or 9 parameter (with lysis) and related 3-4 parameter in vivo in future using multiparametric bioluminescence diagnostics and imaging, respectively We solve unique sets of problems for our customers in the scientific community and industry by offering the first commercial in vivo preclinical dual colour near-infrared BLI technology for sale and potential for an explosion in the applications of bioluminescence for multiparameter detection and imaging, even clinically. This is primarily a biomedical research acceleration technology based around a chemical compound called infraluciferin (for which Bioflares Ltd holds the patent rights) and novel engineered high activity and multi-wavelength infraluciferase enzymes. This technology has immediate applications in preclinical cancer, stem cell, gene therapy, vaccinology and biological development research both in animals, and in cells, so that in future we can eliminate animal use from science. We also aim to eliminate the use of radiation in human cancer imaging. Biomedicine helps us overcome innumerable diseases and improves the quality of our lives by unravelling how mammalian life is composed and functions, or fixing its faults. Our proprietary non-invasive technology enables scientists and doctors to quickly and easily carry out more complex, clear and accurate bioimaging studies than currently possible in whole living mammals, like simultaneous in vivo testing of chimeric antigen receptor (CAR) T-cell cancer effectors and targets, or 2-3 types of stem-cells, or 2-3 different genes for gene therapy or vaccine development. Faster and better science requires better navigation through complex biological seas, so for medical adventures in a better world scientists need Bioflares